Janux Soars On Early Efficacy, Safety For ‘Masked’ T-Cell Engagers

Phase Ia Studies Show Low Rates Of CRS

 
• By Mandy Jackson
  
Abstract financial graph with uptrend line graph and arrows in stock market on blue color background
Janux went public at $17 in 2021 and is now almost at $50 per share • Source: Shutterstock

More from Clinical Trials

More from R&D